Mr. Andre Larente reports

DIAGNOS ANNOUNCES UPSIZE OF PREVIOUSLY ANNOUNCED BROKERED PRIVATE PLACEMENT TO $3.65M LED BY CENTURION ONE CAPITAL

Diagnos Inc. has upsized its brokered private placement, as previously announced in its news release dated Nov. 10, 2025, due to strong investor demand. Under the amended terms, the company will issue up to 12,166,667 units of the company at 30 cents per unit for aggregate gross proceeds of up to approximately $3.65-million.

Each unit shall consist of one common share in the capital of the company and one common share purchase warrant. Each full warrant shall entitle the holder thereof to purchase one share at a price of 40 cents for a period of 18 months following the closing date (as defined herein). In connection with the offering, the company has also granted the agent an option exercisable at any time prior to two business days prior to the last closing of the offering to increase the size of the offering by an additional 1.75 million units for aggregate gross proceeds of up to approximately an additional $525,000.

The offering is led by Centurion One Capital Corp. as lead agent and sole bookrunner.

The gross proceeds of the offering will be used for regulatory affairs, product development, business development and general corporate purposes.

Subject to compliance with applicable laws, the units to be issued under the offering will be offered by way of private placement in each of the provinces of British Columbia, Alberta, Ontario and Quebec, in the United States pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended, and in jurisdictions outside of Canada and the United States as may be mutually agreed by the company and the lead agent, provided it is understood that no prospectus filing, registration or comparable obligation arises in such other jurisdiction.

The offering is expected to close on or around Dec. 3, 2025, or such other date as agreed upon between the company and the lead agent, and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange. The securities to be issued under the offering will have a hold period of four months and one day from the closing date under applicable Canadian securities laws.

It is anticipated that certain insiders of the company and lead agent may acquire units in the offering in amounts up to approximately 50 per cent of the offering. Any participation by insiders in the offering will constitute a related party transaction, as defined under Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The company expects such participation will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the units subscribed for by the insiders, nor the consideration for the units paid by such insiders, is expected to exceed 25 per cent of the company's market capitalization.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

About Centurion One Capital Corp.

Centurion One Capital's mission is to ignite the world's most visionary entrepreneurs to conquer the greatest challenges of tomorrow, fuelling their ambitions with transformative capital, unparalleled expertise and a global network of influential connections. Every interaction is guided by Centurion One Capital's core values of respect, integrity, commitment, excellence in execution and uncompromising performance. Centurion One Capital makes principal investments, drawing on the time-honoured principles of merchant banking, where aligned incentives forge enduring partnerships.

We seek Safe Harbor.